Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori
Luc De Vuyst1, Pascal Vincent2,3, Eleftherios Makras4
1Research Group of Industrial Microbiology and Food Biotechnology (IMDO), Faculty of Sciences and Bio-engineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Brussels, Belgium. ldvuyst@vub.ac.be.
Certain probiotic lactobacilli, specifically Lactobacillus amylovorus and Lactobacillus johnsonii, produce peptide extracts that effectively inhibit Helicobacter pylori growth. These findings suggest a potential mechanism for probiotics in H. pylori eradication therapies.
Area of Science:
- Microbiology
- Probiotics
- Gastrointestinal Health
Background:
- Probiotic lactobacilli demonstrate inhibitory effects against Helicobacter pylori.
- The precise mechanisms behind this inhibition remain largely unelucidated.
- Understanding these mechanisms is crucial for developing novel H. pylori eradication strategies.
Purpose of the Study:
- To investigate the role of peptide extracts from specific Lactobacillus strains in inhibiting H. pylori.
- To identify which Lactobacillus species produce the most potent antibacterial peptides against H. pylori.
- To confirm the proteinaceous nature of the inhibitory compounds.
Main Methods:
- Preparation of peptide extracts from six Lactobacillus cultures: L. acidophilus La1, L. amylovorus DCE 471, L. casei YIT 9029, L. gasseri K7, L. johnsonii La1, and L. rhamnosus GG.
- Assessing the inhibitory activity of these extracts against H. pylori ATCC 43504 by measuring viability reduction.
- Testing the susceptibility of six clinical H. pylori isolates to the active peptide extracts.
- Evaluating the effect of protease treatment on the inhibitory activity of the peptide extracts.
Main Results:
- Peptide extracts from L. amylovorus DCE 471 and L. johnsonii La1 significantly reduced H. pylori viability by over 2 log units within 4 hours.
- Four other tested Lactobacillus extracts showed minimal or no inhibitory activity.
- Similar potent inhibition was observed with L. amylovorus DCE 471 and L. johnsonii La1 extracts against six clinical H. pylori isolates.
- Protease treatment rendered the extracts inactive, confirming the inhibitory substances are proteinaceous.
Conclusions:
- Peptide extracts from Lactobacillus amylovorus DCE 471 and Lactobacillus johnsonii La1 possess significant antibacterial activity against Helicobacter pylori.
- These findings highlight bacteriocins or other antibacterial peptides produced by specific lactobacilli as key components in H. pylori inhibition.
- The study supports the potential of selected probiotic strains and their derived peptides in therapeutic strategies for H. pylori infection.
More Related Videos
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Inhibitors of Gram-positive Cell Wall Synthesis
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Peptic Ulcer
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...


